Target Price | $327.42 |
Price | $307.42 |
Potential | 6.51% |
Number of Estimates | 27 |
27 Analysts have issued a price target UnitedHealth 2026 . The average UnitedHealth target price is $327.42. This is 6.51% higher than the current stock price. The highest price target is $710.85 131.23% , the lowest is $199.98 34.95% . | |
A rating was issued by 32 analysts: 22 Analysts recommend UnitedHealth to buy, 6 to hold and 4 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the UnitedHealth stock has an average upside potential 2026 of 6.51% . Most analysts recommend the UnitedHealth stock at Purchase. |
26 Analysts have issued a sales forecast UnitedHealth 2025 . The average UnitedHealth sales estimate is $454b . This is 7.29% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $480b 13.48% , the lowest is $431b 1.84% .
This results in the following potential growth metrics:
2024 | $400b | 7.71% |
---|---|---|
2025 | $454b | 13.33% |
2026 | $482b | 6.23% |
2027 | $515b | 6.76% |
2028 | $551b | 7.00% |
2029 | $596b | 8.21% |
2030 | $597b | 0.22% |
2031 | $629b | 5.29% |
2032 | $662b | 5.28% |
24 Analysts have issued an UnitedHealth EBITDA forecast 2025. The average UnitedHealth EBITDA estimate is $26.5b . This is 24.23% lower than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $29.4b 16.05% , the lowest is $25.2b 28.00% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $36.4b | 0.15% |
---|---|---|
2025 | $26.5b | 27.16% |
2026 | $29.3b | 10.47% |
2027 | $32.8b | 11.92% |
2028 | $49.7b | 51.54% |
2029 | $54.9b | 10.54% |
2030 | $59.6b | 8.54% |
2031 | $63.4b | 6.44% |
2032 | $67.5b | 6.46% |
2024 | 9.09% | 7.02% |
---|---|---|
2025 | 5.84% | 35.75% |
2026 | 6.08% | 4.11% |
2027 | 6.37% | 4.77% |
2028 | 9.02% | 41.60% |
2029 | 9.21% | 2.11% |
2030 | 9.98% | 8.36% |
2031 | 10.09% | 1.10% |
2032 | 10.20% | 1.09% |
30 UnitedHealth Analysts have issued a net profit forecast 2025. The average UnitedHealth net profit estimate is $20.2b . This is 4.94% lower than the net profit for the last 12 months(TTM). The highest net profit forecast is $25.2b 18.26% , the lowest is $16.0b 24.86% .
This results in the following potential growth metrics and future Net Margins:
2024 | $14.4b | 35.64% |
---|---|---|
2025 | $20.2b | 40.53% |
2026 | $23.5b | 15.86% |
2027 | $26.8b | 14.34% |
2028 | $33.2b | 23.74% |
2029 | $37.9b | 14.07% |
2030 | $42.0b | 10.91% |
2031 | $47.3b | 12.70% |
2032 | $53.3b | 12.55% |
2024 | 3.60% | 40.25% |
---|---|---|
2025 | 4.46% | 23.93% |
2026 | 4.87% | 9.19% |
2027 | 5.21% | 6.98% |
2028 | 6.03% | 15.74% |
2029 | 6.36% | 5.47% |
2030 | 7.03% | 10.53% |
2031 | 7.53% | 7.11% |
2032 | 8.05% | 6.91% |
30 Analysts have issued a UnitedHealth forecast for earnings per share. The average UnitedHealth EPS is $22.32 . This is 4.62% lower than earnings per share in the financial year 2024. The highest EPS forecast is $27.76 18.63% , the lowest is $17.64 24.62% .
This results in the following potential growth metrics and future valuations:
2024 | $15.51 | 35.00% |
---|---|---|
2025 | $22.32 | 43.91% |
2026 | $25.86 | 15.86% |
2027 | $29.56 | 14.31% |
2028 | $36.58 | 23.75% |
2029 | $41.73 | 14.08% |
2030 | $46.29 | 10.93% |
2031 | $52.17 | 12.70% |
2032 | $58.71 | 12.54% |
Current | 12.96 | 65.91% |
---|---|---|
2025 | 13.59 | 4.83% |
2026 | 11.73 | 13.69% |
2027 | 10.26 | 12.53% |
2028 | 8.29 | 19.20% |
2029 | 7.27 | 12.30% |
2030 | 6.55 | 9.90% |
2031 | 5.82 | 11.15% |
2032 | 5.17 | 11.17% |
Based on analysts' sales estimates for 2025, the UnitedHealth stock is valued at an EV/Sales of 0.71 and an P/S ratio of 0.61 .
This results in the following potential growth metrics and future valuations:
Current | 0.76 | 51.90% |
---|---|---|
2025 | 0.71 | 6.63% |
2026 | 0.67 | 5.86% |
2027 | 0.63 | 6.33% |
2028 | 0.58 | 6.55% |
2029 | 0.54 | 7.58% |
2030 | 0.54 | 0.22% |
2031 | 0.51 | 5.03% |
2032 | 0.49 | 5.02% |
Current | 0.65 | 53.05% |
---|---|---|
2025 | 0.61 | 6.80% |
2026 | 0.57 | 5.86% |
2027 | 0.53 | 6.33% |
2028 | 0.50 | 6.55% |
2029 | 0.46 | 7.58% |
2030 | 0.46 | 0.22% |
2031 | 0.44 | 5.04% |
2032 | 0.42 | 5.01% |
Analyst | Rating | Action | Date |
---|---|---|---|
B of A Securities |
Neutral
➜
Neutral
|
Unchanged | Aug 18 2025 |
JP Morgan |
Overweight
➜
Overweight
|
Unchanged | Aug 06 2025 |
Wells Fargo |
Overweight
➜
Overweight
|
Unchanged | Aug 04 2025 |
Baird |
Neutral
➜
Underperform
|
Downgrade | Jul 31 2025 |
Keybanc |
Overweight
➜
Overweight
|
Unchanged | Jul 30 2025 |
B of A Securities |
Neutral
➜
Neutral
|
Unchanged | Jul 30 2025 |
Oppenheimer |
Outperform
➜
Outperform
|
Unchanged | Jul 30 2025 |
Analyst Rating | Date |
---|---|
Unchanged
B of A Securities:
Neutral
➜
Neutral
|
Aug 18 2025 |
Unchanged
JP Morgan:
Overweight
➜
Overweight
|
Aug 06 2025 |
Unchanged
Wells Fargo:
Overweight
➜
Overweight
|
Aug 04 2025 |
Downgrade
Baird:
Neutral
➜
Underperform
|
Jul 31 2025 |
Unchanged
Keybanc:
Overweight
➜
Overweight
|
Jul 30 2025 |
Unchanged
B of A Securities:
Neutral
➜
Neutral
|
Jul 30 2025 |
Unchanged
Oppenheimer:
Outperform
➜
Outperform
|
Jul 30 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.